Adhd

North Carolina

43 Adhd Trials near North Carolina

Power is an online platform that helps thousands of Adhd patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

NRCT-101SR for ADHD

Decatur, Georgia
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:13 - 17

160 Participants Needed

Evening Dosed Methylphenidate for ADHD

Decatur, Georgia
This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:4 - 5

168 Participants Needed

Centanafadine for ADHD

Charlotte, North Carolina
This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 18

680 Participants Needed

Azstarys® for ADHD

Decatur, Georgia
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:4 - 5

123 Participants Needed

SPN-812 for ADHD

Durham, North Carolina
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:48 - 69

286 Participants Needed

NRCT-101SR + NRCT-202XR for ADHD

Decatur, Georgia
A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:13 - 17

60 Participants Needed

Mindfulness Practices for ADHD

Spartanburg, South Carolina
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that commonly persists into adulthood and is associated with significant life impairments. The current study evaluates the feasibility, acceptability, and preliminary efficacy of a group-based mindfulness intervention for first-year college students with ADHD. If found to be feasible, acceptable, and efficacious, subsequent research will examine its impact on a larger scale to have a broader public health impact for college students with ADHD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:17 - 25

100 Participants Needed

Question Prompt/Video Intervention for ADHD

Chapel Hill, North Carolina
The investigators propose to conduct a pilot randomized controlled feasibility trial to evaluate the feasibility and effectiveness of a pre-visit intervention to improve communication about attention deficit hyperactivity disorder. The investigators will enroll 140 English-speaking youth ages 11-17 with an ADHD medical record diagnosis who screen as having predominantly inattentive subtype, hyperactive/impulsive subtype, or combined inattention/hyperactivity on the Vanderbilt parent assessment scale from three pediatric clinics. Teh investigators will randomize the families to receive both the question prompt lists and video (N=35), just the question prompt lists (N=35), just the video (N=35), or usual care (N=35). This will allow the team to understand whether both the video and question prompt list components are needed for the larger trial. The aims of the investigators are: Aim 1: To examine whether the ADHD question prompt lists and/or pre-visit video significantly impact the proposed mechanisms of the intervention. The team will investigate whether adolescents and parents in each of the intervention groups: (a) ask more questions and receive more provider education about ADHD during their baseline and 3-month visits and (b) have higher self-efficacy at 3 and 6 months than adolescents and parents in the usual care group. Aim 2: To investigate the effectiveness of the ADHD question prompt lists and/or the pre-visit video by examining whether adolescents in each of the intervention groups have improved ADHD symptoms, school and social performance, and quality-of-life at 6 months compared to those in the usual care group. Aim 3: To assess adolescent, parent, and provider feedback on the acceptability, feasibility, tolerability, and safety of using the ADHD question prompt lists and/or the pre-visit video. The results from this pilot trial will be used to inform a larger trial by: (a) identifying the intervention arm with the greatest potential impact, acceptability, feasibility, and tolerability, and (b) determine the best mechanisms and outcome variables to assess in a larger trial.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:11 - 17

140 Participants Needed

Telehealth Intervention for Preschool ADHD

Durham, North Carolina
This study will be investigating two telehealth interventions for preschoolers with ADHD. The study is divided into two Aims. During Aim 1, caregivers of preschoolers with attention concerns, pediatric behavioral health professionals, and pediatric primary care providers will take part in two virtual focus groups to provide their perspective on ways to improve the telehealth intervention being evaluated.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:3 - 5

44 Participants Needed

Stress Test for Substance Addiction

Chapel Hill, North Carolina
Purpose: This 5-year R01 study will elucidate the role of maturational change across adolescence in neural connectivity and physiological stress responses in the relationship between anxiety and adverse pathways to substance use (APSU). Participants: Children (N=200) aged 12-14 with symptoms of anxiety and their legal caregiver will be recruited from clinical and community sources. Procedures: Youth participants will complete several questionnaires and interviews, undergo neuroimaging while performing cognitive tasks, and have their heart rate and skin conductance monitored during a mildly stressful task. Caregivers will complete several questionnaires.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 14

180 Participants Needed

Behavioral Health Care for Mental Health Disorders and HIV/AIDS

Charlotte, North Carolina
The goal of this treatment study is to learn about the mental health, substance use and physical health outcomes associated with participating in the EASE holistic behavioral health and wellness program for individuals identifying as LGBTQ+ and/or living with HIV. The main questions it aims to answer are: 1. Do important health outcomes, including substance use, mental health and social support related outcomes of individuals living with HIV and/or identifying as LGBTQ who participated in the holistic behavioral health and wellness program change after study participation? 2. Does a tailored approach to meet the specific needs of different subpopulations including 1) older (40+) PLWH and/or LGBTQ individuals with or at risk for additional health comorbidities and 2) PLWH and/or LGBTQ young adults (18-40) improve health outcomes including improvement in health and health behaviors . Participants will be asked to: * participate in 6 months of behavioral health treatment tailored to their needs, which may include individual counseling, group counseling, case management, peer support, and related education. * Complete surveys at the time of study entry and 6 months later to measure changes in health outcomes over time.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

200 Participants Needed

SAAF Program for Adolescent Well-Being

Athens, Georgia
The Health and Resilience Project (HARP): Foundations is investigating the efficacy of the Strong African American Families (SAAF) intervention in promoting the health and well being of African American adolescents. Youth age 10-13 and their primary caregivers are randomly assigned to receive SAAF or to a control group. Participants complete baseline and follow-up measures regarding vulnerability to substance use based on a neuroimmune model of stress coping.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 13

650 Participants Needed

Performance-Based Strategy for Substance Abuse Intervention

Research Triangle Park, North Carolina
An experiment to test the effectiveness of providing monetary bonuses to staff for achieving pre-defined performance targets regarding the implementation of a motivational interviewing-based brief intervention for substance use.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

428 Participants Needed

Naltrexone + Bupropion for Methamphetamine Addiction

Pickens, South Carolina
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine use disorder (MUD) seeking to stop or reduce MA use.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

360 Participants Needed

Varenicline for Smoking

Durham, North Carolina
In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that the investigators offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:21+

400 Participants Needed

Varenicline + Counseling for Smoking Addiction

Pickens, South Carolina
The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 40

105 Participants Needed

Varenicline for Alcoholism

Decatur, Georgia
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

30 Participants Needed

TMS + Counseling + Nicotine Replacement for Smoking Cessation

Durham, North Carolina
Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

50 Participants Needed

Combined Adductoplasty™ and Lapiplasty® Surgery for Bunions

Morrisville, North Carolina
Prospective, multicenter, unblinded study to evaluate outcomes of the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure for patients in need of metatarsus adductus and hallux valgus correction. Up to 80 subjects will be treated in this study at up to 13 clinical sites. Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 65

80 Participants Needed

Specialized Post-Incarceration Care for Opioid Addiction

Chapel Hill, North Carolina
TCN PATHS will recruit an anticipated 400 participants who are prescribed MOUD who are released from detention facilities. Each individual will be randomized to either 1) standard primary care (SPC) or 2) a Transitions Clinic Network (TCN) program primary care. Participants will be followed for a year and complete surveys at baseline and at month 1, 3, 6, 9, and 12. At each of these points research staff will confirm MOUD status. Urine drug screenings will be completed at baseline, month 1, 6, and 12 if the participant is not incarcerated. When possible, research staff will collect electronic health records.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

400 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Youth Engagement Strategy for Opioid Use Disorder

Winston-Salem, North Carolina
Phase 1 will consist of a small pilot Open Trial (OT). The objective of Phase 1 is to develop an organization-level Youth Engagement (YE) prevention strategy and implement it in a community-based organization to test feasibility and acceptability in an open trial with one organization. This will include developing a manual for systematically incorporating YE into prevention efforts in community settings. Phase 2 will consist of a small pilot Randomized Controlled Trial (RCT). Four prevention organizations will be randomized either to include Youth Engagement in prevention efforts (treatment) or not (control). The study team will attempt to match the treatment and control groups on relevant characteristics such as geographic location (e.g., urban, rural), population served (e.g., church-based, school-based), and/or prior Youth Engagement involvement. The objective of the second phase of this study is to evaluate the preliminary effectiveness of YE as a prevention strategy for opioid misuse in a small pilot randomized control trial (RCT). This pilot study will examine the effects of the YE prevention strategy on (a) organization-level outcomes, such as perceived value added to prevention programming and (b) individual-level outcomes such as personal skills and attitudes as well as knowledge and attitudes about substances including opioids. Up to 15 leaders/staff and 45 youth/young adults (60 people overall) will be recruited for the study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:11+

60 Participants Needed

Smoking Cessation App for Mental Health Disorders

Durham, North Carolina
This trial will test a new smartphone app called Quit on the Go, designed to help people with serious mental illness quit smoking. The study will compare this app to traditional methods, with both groups also using nicotine patches and gum. The goal is to see if the app helps more people quit smoking and if it is cost-effective.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

450 Participants Needed

Nicotine Exposure for Understanding Cigarette Addiction

Durham, North Carolina
The purpose of this study is to evaluate how certain childhood experiences influences brain function and responses to nicotine exposure in a group of nonsmoking young adults. The investigators assess responses to nicotine exposure by giving participants a small amount of nicotine or placebo, and then asking them to answer questionnaires. The investigational drugs used in this study are a nicotine nasal spray (i.e., Nicotrol) and/or a nasal spray placebo (made of common kitchen ingredients, including a very tiny amount of pepper extract also called capsaicin). The investigators assess brain function through function magnetic resonance imaging (fMRI), which is a noninvasive procedure that uses a magnetic field to take pictures of your brain while you are performing certain tasks. This study will help us to learn more about why some childhood experiences (adverse childhood experiences, or ACEs) contribute to increased risk for smoking and other substance use.

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 21

150 Participants Needed

Contingency Management for PTSD

Durham, North Carolina
Posttraumatic stress disorder (PTSD) is a disabling psychiatric disorder that affects 20%-30% of U.S. Veterans. PTSD is strongly associated with increased risk for substance abuse comorbidity, including cannabis use disorder. Multiple states now include PTSD as a condition for which patients can be legally prescribed medical marijuana, despite the fact that there has not been a single large-scale randomized clinical trial demonstrating the efficacy of cannabis to treat PTSD to date. The overall objective of the current proposal is to study the impact of reduced cannabis use on functioning among Veterans with PTSD. The investigators will evaluate the relationship between cannabis use and daily functioning among cannabis users and heavy cannabis users. The central hypothesis is that reductions in cannabis use will lead to positive changes in the functional outcomes of Veterans. The rationale for this research is that it will provide the first and only real-time data concerning the impact of reduced cannabis use on daily functioning among Veterans with PTSD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

40 Participants Needed

Ketamine for Methamphetamine Use Disorder

Greenville, South Carolina
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

120 Participants Needed

Social Media Intervention for Opioid Abuse

Columbia, South Carolina
Brief Summary The purposes of this study are to develop and implement a peer-led intervention program on Instagram for promoting prescription opioid use management and fostering psychosocial skills among young adults who engage in non-medical use of prescription opioids in the United State. The specific aims of the study include: (1) To implement and test the feasibility of the 12-week peer-led intervention modules on Instagram among young adults who are randomly assigned to either receive the intervention (intervention group) or not receive the intervention (control group) Participants who are assigned to the intervention group will be paired with a peer leader and attend to peer-guided interactive modules on Instagram over 12 weeks. They will complete an online survey at 1st week and 12th week, as well as brief evening surveys every two days during the intervention. The control group will not take part in intervention activities but will complete an online survey at 1st week and 12th week.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 25

70 Participants Needed

Tiratricol Withdrawal for Monocarboxylate Transporter 8 Deficiency

Hillsborough, North Carolina
This is a double-blind, randomized phase 3 multicenter placebo-controlled study in at least 16 evaluable male participants diagnosed with MCT8 deficiency. Male participants, from 4 years of age (at randomization) and having demonstrated stable maintenance treatment with tiratricol, will be randomized to receive placebo or tiratricol for 30 days or until reaching rescue criterion (serum total triiodothyronine \[T3\] \> upper limit of normal \[ULN\] of the participant's normal range, for a sample collected during the 30-day Randomized Treatment Period). The research hypothesis to be tested is that, for participants in the placebo group, removal of tiratricol will lead to an increase of serum total T3 concentration, measured by liquid chromatography with tandem mass spectrometry (LC/MS/MS), above the ULN and requirement of rescue treatment with tiratricol, compared to those who continue to receive tiratricol.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:4+
Sex:Male

16 Participants Needed

Multi-level Intervention for Childhood Cancer Survivorship Care Adherence

Chapel Hill, North Carolina
More than 80% of childhood cancer survivors develop serious or life-threatening late effects after cancer therapy, but \<20% receive recommended survivorship care offered at cancer center survivorship clinics. In a shared care model, the investigators propose to investigate an innovative multi-level intervention consisting of: 1) patient survivorship education via telehealth with the cancer center, 2) ongoing patient-tailored education program within the electronic health record patient portal, 3) a structured interactive phone communication between the cancer center and the primary care clinic, and 4) an in-person visit with the primary care clinic for survivorship care with the goal of achieving high rates of adherence to recommended surveillance for late effects, as well as improving patient and physician knowledge and self-efficacy. If this scalable intervention demonstrates patient completion of recommended care comparable to cancer center survivorship clinics, this innovative study has the enormous potential to deliver recommended care to a larger proportion of childhood cancer survivors and reduce survivorship care disparities, while engaging p to integrate survivorship care as part of overall, lifelong health maintenance.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:2+

240 Participants Needed

Metformin for Breast Cancer Prevention

Seneca, South Carolina
This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may prevent breast cancer.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:25 - 55
Sex:Female

86 Participants Needed

Juveena Hydrogel System for Asherman's Syndrome

Morrisville, North Carolina
This trial is testing if Juveena hydrogel can safely and effectively reduce scar tissue formation in women who have had certain types of uterine surgeries. The gel is applied inside the uterus to prevent the walls from sticking together during healing.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Sex:Female

150 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Adhd clinical trials in North Carolina pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Adhd clinical trials in North Carolina work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Adhd trials in North Carolina 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in North Carolina for Adhd is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in North Carolina several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Adhd medical study in North Carolina?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Adhd clinical trials in North Carolina?

Most recently, we added Social Media Intervention for Opioid Abuse, Varenicline for Smoking and Varenicline for Alcoholism to the Power online platform.

How to manage ADHD without Adderall?

Think of ADHD care without Adderall as three pillars: 1) proven skills training such as cognitive-behavioral therapy or parent/teacher coaching, which meta-analyses show can meaningfully cut inattentive and impulsive symptoms; 2) daily habits that boost brain chemicals—consistent aerobic exercise, 7-9 hours of sleep, and a balanced, low-sugar diet—each backed by research to modestly improve focus; 3) targeted add-ons (omega-3 fish-oil supplements, mindfulness practice, or professionally guided neurofeedback) that have small but credible benefits for some people. Work with a clinician to combine, test, and adjust these pieces every few months so you know what is actually helping and can add non-stimulant medicines later if needed.

Are we over diagnosing ADHD?

Rates of ADHD diagnosis have climbed, and studies confirm that some children—especially the youngest in a class or from more advantaged families—get the label and medication they may not truly need. At the same time, girls, adults, and many minorities with real symptoms are often missed, so the issue is less “too much” diagnosis overall and more “diagnosis in the wrong people.” Asking for a full evaluation that checks symptoms in several settings and rules out sleep, mood, or learning problems is the best safeguard against both mistakes.

What is the latest research on ADHD?

Recent work is mapping ADHD on two fronts: cause and treatment. On the biology side, a 2023 genome-wide study involving >40 000 people pinpointed 30+ gene regions, MRI scans show disrupted communication between attention- and reward-circuits, and several studies find distinct gut-bacteria patterns in both kids and adults—together suggesting ADHD arises from a mix of genes, brain-network wiring and (still-early) gut influences. Translating this, clinicians now have newer options beyond classic stimulants—FDA-approved viloxazine XR, long-acting patches, the prescription video-game EndeavorRx, and small but promising trials of neurofeedback and cognitive training—so ask your doctor about standard medications plus these emerging tools that may soon allow more personalized care.

Does Johnny Depp have ADHD?

There is no credible public record—interview, court document, or medical statement—showing that Johnny Depp has been formally diagnosed with ADHD; the claim stems from unsourced online lists that repeat each other. Until Depp or a qualified clinician confirms otherwise, any statement that he “has ADHD” should be treated as unverified speculation; if you need information about ADHD, rely on a licensed health professional, not celebrity rumors.

What is the 80 20 rule ADHD?

For someone with ADHD, the 80/20 rule means spotting the 20 % of tasks or habits that create about 80 % of your desired results—then protecting time and attention to do those first, ideally when your medication or energy is at its peak. This cuts overwhelm because you give yourself permission to ignore low-impact busywork and instead break the high-impact tasks into small, doable steps (using timers, alerts, or an accountability partner). Think of it as a focusing lens, not a cure; pair it with your regular ADHD treatments and adjust the “vital 20 %” as your goals change.

Is ADHD a disability?

Yes—ADHD is treated as a disability when the symptoms are strong enough to “substantially limit” everyday activities like focusing, learning, or working, which is exactly how U.S. laws such as the ADA, Section 504, and Social Security define disability. A diagnosis alone isn’t enough; you need documentation that the condition is causing real-world problems, after which schools, employers, or benefit programs must consider reasonable supports (extra time, quiet workspace, flexible scheduling, etc.). If you think ADHD is holding you back, gather medical records and examples of how it affects your tasks and formally ask for accommodations or benefits under the relevant program.

What makes ADHD people happy?

Studies show that people with ADHD feel happiest when four things line up: (1) their core symptoms are tamed with medication and/or ADHD-specific therapy, (2) predictable routines, reminders, exercise, and good sleep cut daily chaos, (3) they spend real time in activities that match their high interests and creativity, and (4) they’re surrounded by family, friends, or support groups that understand ADHD rather than shame it. Put simply: treat the symptoms, externalize organization, lean into your passions, and stay connected to people who “get” you—those combined levers consistently raise quality-of-life scores for both kids and adults with ADHD.

How much weight did you lose on ADHD medication?

Weight loss on stimulant ADHD medicines is usually modest and highly individual—clinical trials show average drops of about 3–5 lb (1–2 kg) in the first month and roughly 6–10 lb (3–4 kg) over the first 3–6 months, with only one-third of people losing more than 5 % of their starting weight before the effect levels off. Weigh yourself (or your child) weekly; if you see more than a 10 % fall from baseline or a slowdown in growth, talk with the prescriber about dose timing, nutrition strategies, or switching to a non-stimulant option.

What makes ADHD worse in adults?

Anything that further strains the brain’s self-regulation system can flare adult ADHD: lack of sleep or exercise, chronic stress, unmanaged anxiety/depression, inconsistent medication or substance use, hormonal shifts, and chaotic, screen-heavy environments. Focus on the controllables—protect 7-9 h of sleep, move daily, eat regular balanced meals, keep spaces and schedules simple, treat co-existing mood issues, and take medication exactly as prescribed—then review persisting problems with your clinician.

Is there still ADHD med shortage?

Yes—into 2024 many pharmacies still report spot shortages of popular stimulant ADHD medicines, especially immediate-release Adderall, several methylphenidate/Concerta generics, and some Vyvanse doses, because factory slow-downs and federally capped production haven’t kept up with rising prescriptions. Availability varies week-to-week and by location, so call a few pharmacies early, ask if a different strength or brand is in stock, and have your prescriber ready to adjust the prescription or discuss a short-term non-stimulant alternative if needed.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

187 Clinical Trials near Bel Air, MD

58 Arthritis Trials near Tampa, FL

Top Clinical Trials near Duncanville, TX

Top Clinical Trials near Bellevue, OH

183 Clinical Paid Trials near Madison, WI

Top Acne Clinical Trials

Top Anemia Clinical Trials

Top Clinical Trials near Elizabeth, NJ

Top Depression Clinical Trials near Philadelphia, PA

63 Prostate Cancer Trials near Cincinnati, OH

Top Clinical Trials near Humble, TX

Top Sjia Clinical Trials

By Trial

YTB323 for Myasthenia Gravis

Sacituzumab Govitecan for Breast Cancer

Multiple Treatments for Skin Tumors

Radiofrequency Microneedling for Melasma

Ketorolac Injection for Kidney Stones

Psychological Care Strategies for Depression and Anxiety

ABX464 Maintenance Therapy for Ulcerative Colitis

Pimavanserin for Autism

Financial Navigation for Cancer Patients

Psilocybin Group Therapy for Cancer-Related Anxiety

bb2121 for Multiple Myeloma

Stem Cells for Retinal Disease

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial